์๋๋กํฌ๋
์๋๋กํฌ๋์ ์ํจ์ฑ, ๊ฐ์ญ์ ์์ธํธ์ฝ๋ฆฐ์์คํ ๋ผ์์ ์ต์ ์ ๋ก, ์์ํ์์ ์ฃผ๋ก **์ค์ฆ ๊ทผ๋ฌด๋ ฅ์ฆ** ์ง๋จ(ํ ์ค๋ก ๊ฒ์ฌ)์ ์ฌ์ฉ๋ฉ๋๋ค. ๋ํ ๊ทผ๋ฌด๋ ฅ์ฑ ์๊ธฐ(์น๋ฃ ๋ถ์กฑ)์ ์ฝ๋ฆฐ์ฑ ์๊ธฐ(๊ณผ๋ค ์น๋ฃ)๋ฅผ ๊ตฌ๋ณํ๊ณ , ๋ฏธ์ฃผ์ ๊ฒฝ ํจ๊ณผ๋ฅผ ํตํด ์ฌ๋ฐฉ ๋น๋งฅ์ ์น๋ฃํ๋ฉฐ, ๋นํ๋ถ๊ทน์ฑ ์ ๊ฒฝ๊ทผ ์ฐจ๋จ์ ๋ฅผ ๊ธธํญํ๋ ๋ฐ ์ฌ์ฉ๋ฉ๋๋ค. > **์์ ๊ฒฝ๊ณ :** ์ฌ๊ฐํ ์๋งฅ์ด๋ ์ฌ์์ถ๋ถ์ ์ ์ํ์ด ์์ผ๋ฏ๋ก ์๋๋กํฌ๋ ๊ฒ์ฌ๋ฅผ ์ํํ ๋๋ ํญ์ ์ํธ๋กํ์ ์ฃผ์ฌ๊ธฐ์ ์ค๋นํด ๋์ด์ผ ํฉ๋๋ค.
์์ฉ ๊ธฐ์ : Edrophonium acts as a reversible and short-acting competitive inhibitor of the enzyme **acetylcholinesterase** at the neuromuscular junction. **Acetylcholine** release โ binds to receptors โ normally broken down by acetylcholinesterase. Edrophonium blocks this enzyme โ **acetylcholine** accumulates โ prolonged and increased stimulation of nicotinic and muscarinic receptors, temporarily improving muscle strength in myasthenia gravis.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Mechanical gastrointestinal obstruction
- Mechanical urinary tract obstruction
- Peritonitis
์ด์๋ฐ์
- Nausea
- Vomiting
- Increased salivation
- Diarrhoea
- Muscle fasciculations
- Severe bradyarrhythmias
- Asystole
์ฝ๋ฌผ ์ํธ์์ฉ
- Depolarizing neuromuscular relaxants (e.g., suxamethonium) ยท Potentiates neuromuscular blockade ยท major
๋ชจ๋ํฐ๋ง
- Heart rate and rhythm (ECG recommended during administration)
- Respiratory rate and effort
- Muscle strength and tone
- Cholinergic signs (salivation, vomiting, defecation)
๊ณผ์ฉ๋
Overdosage may lead to **muscle fasciculations** and **paralysis**. Severe bradyarrhythmias, even asystole, may occur if edrophonium is used to antagonize neuromuscular block without the co-injection of atropine. > **Treatment:** Respiration should be supported and **atropine** administered IV to counteract muscarinic effects.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.